Medical Deep Learning Company 12Sigma Sweeps MI Diagnosis Competition
COVID-19 and China
12 Sigma Medical Imaging Diagnosis System. Photo: 12 Sigma

12 Sigma won a tumour diagnosis competition, LiTS - Liver Tumor Segmentation Challenge, outscoring 1328 global MI Diagnosis and AI teams. Participants competed in developing automatic segmentation algorithms to segment liver lesions in contrast­-enhanced abdominal CT scans.

For the competition, the data provided by various clinical sites around the world and the training data set contains 130 CT scans. The challenge is organised in conjunction with international biomedical imaging standards. 

12 Sigma's AI enhanced liver CT (Computerized Tomography) automatically detects the 3D surface of the liver segmentation and quantifies liver forms. It helps doctors perform an automatic analysis and detection of deep-inside tumours supporting the follow-up tracking of patients and improving the medical evidence base for patients. The system empowers doctors to make accurate and efficient clinical diagnoses and reduce workload. The system is applicable to radiology, clinical departments and imaging centres.

12 Sigma's intelligent diagnosis solutions focus on real clinical needs; covering the whole process of disease-monitoring, quantitative analysis, disease classification, benign and malignant judgment, follow-up and medical report generation. It can halve the process for radiologists and clinicians. 

The company's products focus on the high incidence areas of Chinese patients such as tumours and cardiovascular and cerebrovascular diseases. They can automatically segment organs from CT, MRI, X-ray, PET/CT and ultrasound images, automatically mark the tissue structure of suspected lesions, measure their location, size, shape and other quantitative information, and can also be used to segment organs from medical images such as CT, MRI, X-ray, PET/CT and ultrasound. The benign and malignant lesions were judged.

Founded in 2015, 12 Sigma is a high-tech enterprise focusing on the research and development of the world's top intelligent medical imaging diagnosis systems. Presently, its products cover a relatively complete system of medical image-assisted diagnosis products. The company's products cover more than 200 hospitals, and the company has reached scientific research cooperation with more than 30 top hospitals in the mainland and overseas. The company's global layout has gradually deepened and has completed overseas distribution in the United States, Japan, Europe and other countries. It has also cooperated with local strategic partners and top research institutes. 






Latest Updates:

See Also

Communicate Directly with the Author!

Ask the author questions about the copied text

Research Reports
Editor's Picks